Literature DB >> 27370177

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.

Sebastien Antoni1, Jacques Ferlay1, Isabelle Soerjomataram1, Ariana Znaor1, Ahmedin Jemal2, Freddie Bray3.   

Abstract

CONTEXT: Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012.
OBJECTIVE: We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. EVIDENCE ACQUISITION: Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). EVIDENCE SYNTHESIS: Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries.
CONCLUSIONS: The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. PATIENT
SUMMARY: The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder; Cancer; Incidence; Mortality; Statistics

Mesh:

Year:  2016        PMID: 27370177     DOI: 10.1016/j.eururo.2016.06.010

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  709 in total

1.  ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.

Authors:  Tomasz B Owczarek; Takashi Kobayashi; Ricardo Ramirez; Lijie Rong; Anna M Puzio-Kuter; Gopa Iyer; Min Yuen Teo; Francisco Sánchez-Vega; Jingqiang Wang; Nikolaus Schultz; Tian Zheng; David B Solit; Hikmat A Al-Ahmadie; Cory Abate-Shen
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

2.  PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.

Authors:  Henning Reis; Rene Serrette; Jennifer Posada; Vincent Lu; Ying-Bei Chen; Anuradha Gopalan; Samson W Fine; Satish K Tickoo; Sahussapont J Sirintrapun; Gopa Iyer; Samuel A Funt; Min Yuen Teo; Jonathan E Rosenberg; Dean F Bajorin; Guido Dalbagni; Bernard H Bochner; David B Solit; Victor E Reuter; Hikmat A Al-Ahmadie
Journal:  Am J Surg Pathol       Date:  2019-07       Impact factor: 6.394

3.  Partitioning of time trends in prevalence and mortality of bladder cancer in the United States.

Authors:  Igor Akushevich; Arseniy P Yashkin; Brant A Inman; Frank Sloan
Journal:  Ann Epidemiol       Date:  2020-06-03       Impact factor: 3.797

Review 4.  Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.

Authors:  Adnan El-Achkar; Luis Souhami; Wassim Kassouf
Journal:  Curr Urol Rep       Date:  2018-11-03       Impact factor: 3.092

5.  Cancer survival in adult patients in Spain. Results from nine population-based cancer registries.

Authors:  M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez
Journal:  Clin Transl Oncol       Date:  2017-07-17       Impact factor: 3.405

6.  Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC).

Authors:  Jean Carlo F Datovo; Wilmar Azal Neto; Gustavo B Mendonça; Danilo L Andrade; Leonardo O Reis
Journal:  World J Urol       Date:  2019-02-25       Impact factor: 4.226

Review 7.  Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.

Authors:  Heather Katz; Emnet Wassie; Mohamed Alsharedi
Journal:  Med Oncol       Date:  2017-09-01       Impact factor: 3.064

Review 8.  Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.

Authors:  Besma Abbaoui; Christopher R Lucas; Ken M Riedl; Steven K Clinton; Amir Mortazavi
Journal:  Mol Nutr Food Res       Date:  2018-08-29       Impact factor: 5.914

9.  Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis.

Authors:  Sho Sugawara; Yasutaka Yamada; Takayuki Arai; Atsushi Okato; Tetsuya Idichi; Mayuko Kato; Keiichi Koshizuka; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2018-03-14       Impact factor: 3.172

10.  Circ_0008532 promotes bladder cancer progression by regulation of the miR-155-5p/miR-330-5p/MTGR1 axis.

Authors:  Liang Chen; Xiong Yang; Jun Zhao; Ming Xiong; Raya Almaraihah; Zhaohui Chen; Teng Hou
Journal:  J Exp Clin Cancer Res       Date:  2020-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.